## 17347

## Phospho-Chk1 (Ser280) Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

## For Research Use Only. Not for Use in Diagnostic Procedures.

<b>Applications:</b> W	Reactivity: H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 56	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #O14757	Entrez-Gene Id: 1111
Product Usage Information		<b>Application</b> Western Blotting			<b>Dilution</b> 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		Phospho-Chk1 (Ser280) Antibody detects endogenous levels of Chk1 only when phosphorylated at serine 280.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser280 of human Chk1. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		Chk1 kinase acts downstream of ATM/ATR kinase and plays an important role in DNA damage checkpoint control, embryonic development, and tumor suppression (1). Activation of Chk1 involves phosphorylation at Ser317 and Ser345 by ATM/ATR, followed by autophosphorylation of Ser296. Activation occurs in response to blocked DNA replication and certain forms of genotoxic stress (2). While phosphorylation at Ser345 serves to localize Chk1 to the nucleus following checkpoint activation (3), phosphorylation at Ser317 along with site-specific phosphorylation of PTEN allows for re-entry into the cell cycle following stalled DNA replication (4). Chk1 exerts its checkpoint mechanism on the cell cycle, in part, by regulating the cdc25 family of phosphatases. Chk1 phosphorylation of cdc25A targets it for proteolysis and inhibits its activity through 14-3-3 binding (5). Activated Chk1 can inactivate cdc25C via phosphorylation at Ser216, blocking the activation of cdc2 and transition into mitosis (6). Centrosomal Chk1 has been shown to phosphorylate cdc25B and inhibit its activation of CDK1-cyclin B1, thereby abrogating mitotic spindle formation and chromatin condensation (7). Furthermore, Chk1 plays a role in spindle checkpoint function through regulation of aurora B and BubR1 (8). Research studies have implicated Chk1 as a drug target for cancer therapy as its inhibition leads to cell death in many cancer cell lines (9).  Akt has been shown to phosphorylate Chk1 at Ser280 in vitro, and preliminary data suggests that Akt activity may prevent Chk1 activation (5).				
Background References		1. Liu, Q. et al. (2000) <i>Genes Dev</i> 14, 1448-59. 2. Zhao, H. and Piwnica-Worms, H. (2001) <i>Mol Cell Biol</i> 21, 4129-39. 3. Jiang, K. et al. (2003) <i>J Biol Chem</i> 278, 25207-17. 4. Martin, S.A. and Ouchi, T. (2008) <i>Mol Cancer Ther</i> 7, 2509-16. 5. Chen, M.S. et al. (2003) <i>Mol Cell Biol</i> 23, 7488-97. 6. Zeng, Y. et al. (1998) <i>Nature</i> 395, 507-10. 7. Löffler, H. et al. (2006) <i>Cell Cycle</i> 5, 2543-7. 8. Zachos, G. et al. (2007) <i>Dev Cell</i> 12, 247-60. 9. Garber, K. (2005) <i>J Natl Cancer Inst</i> 97, 1026-8. 10. Shtivelman, E. et al. (2002) <i>Curr. Biol.</i> 12, 919-924.				
Spacios Paacti	.i+v	Species reactivity is de	stormined by testin	g in at least one approve	ad application (a.g.	wastern blot)

**Species Reactivity** Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X

TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human

**Trademarks and Patents** Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

## **Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.